Incyte Corporation Stock News

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics leapt on its own beat-and-raise. The post Incyte, Haemonetics Post Earnings Beats; One Surges Wi

Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) could produce exceptional returns because of its solid growth attributes.

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Opzelura's approval in vitiligo in the USA is the main growth driver. Next driver is Opzelura's approval for the vitiligo treatment in Europe. The issue with Jakafi's LOE may be solved by the developm

It is useful to understand the financial implications for Incyte with its major product, JAKAFI, facing loss of exclusivity ("LOE") in 2028. 2028 is still five years away and JAKAFI continues to provi

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late Ju

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business

LGND vs. INCY: Which Stock Is the Better Value Option?

These two biotechs are flying high right now.

LGND vs. INCY: Which Stock Is the Better Value Option?

These two biotechs are flying high right now.